Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a study of inhaled GRC 17536 in refractory chronic cough
2013-002728-17Phase 2Completed
- Sponsor
- Glenmark Pharmaceuticals SA
- Start
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in refractory chronic cough (RCC) comparing GRC 17536 with Placebo (2 arms). Primary endpoint: Change in log 24-hour cough frequency. Started Jul 2013; status: completed.
02
Drugs
GRC-17536
03
Conditions
refractory chronic cough (RCC)
Beyond the preview
Go deeper on 2013-002728-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002728-17.